Infographic: 3 Takeaways About Biosimilar Filgrastim from the 2017 ASH Meeting

Our latest infographic provides 3 key takeaways from the American Society of Hematology's (ASH) 59th Annual Meeting and Exposition.

Related Content:

Oncology

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

Denosumab, Golimumab Biosimilars Clear Major Regulatory Milestones in Europe, as US Hurdles Remain

Medicare Modeling Shows Major Savings With Biosimilar Bevacizumab Use